~~<i id='85A301B3D4'><strike id='85A301B3D4'><tt id='85A301B3D4'><pre id='85A301B3D4'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：knowledge 2025-09-27 07:40:18 Page View：288

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ER docs worry over extreme heat as a 'mass casualty event'
Next article： Medical records are filled with copy

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

What Henrietta Lacks settlement says about racism in medicine

ApaintingofHenriettaLacksHenriettaLacksHouseofHealingForwhatwouldhavebeenHenriettaLacks’103thbirthda

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Argenx readies a blockbuster opportunity with drug for autoimmune disease

MollyFerguson/STATHaveyouheardthenews?I’mlaunchingaweeklyemailnewsletterstartingonMarch28.It’scalled